Amneal Pharmaceuticals, Inc.

AMRX | $6.07 12.41% 11.04% 3.1M

(0.0% 1d) (-8.6% 1m) (215.8% 1y) (0.0% 2d) (0.6% 3d) (0.7% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 1,872,924,164
http://www.amneal.com
Sec Filling | Patents | 5500 employees

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

injection dividends

Drugs

Zolmitriptan (Zolmitriptan)
ZOMIG (Zolmitriptan)
ZOMIG ZMT (Zolmitriptan)

add to watch list Paper trade email alert is off

Press-releases

Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M

Health Technology

| 0.0% | O: 4.72% H: 0.0% C: 0.0%
fda opioid approval treatment for spray

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M

Health Technology

| -2.53% | O: -1.08% H: 1.09% C: -0.55%
rtu first

Amneal to Report First Quarter 2024 Results on May 3, 2024
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M

Health Technology

| -5.76% | O: -0.52% H: 3.86% C: 0.0%
first report results

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M

Health Technology

| -11.04% | O: 0.0% H: 0.33% C: -2.64%
fda approval

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M

Health Technology

| -7.22% | O: -1.89% H: 1.75% C: 0.0%
ipx203 biotech agreement

Amneal to Participate at Upcoming Investor Conference
Published: 2024-02-13 (Crawled : 13:30) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M

Health Technology

| -7.69% | O: -3.84% H: 2.57% C: -0.45%
conference

Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
Published: 2024-02-08 (Crawled : 21:00) - globenewswire.com
AMRX | $6.07 12.41% 11.04% 3.1M

Health Technology

| -1.1% | O: 0.18% H: 1.83% C: 1.83%
ipx203 drug resubmission application response

I-Mab Signs Agreement to Divest its Assets and Business Operations in China
Published: 2024-02-07 (Crawled : 11:00) - prnewswire.com
AMRX | $6.07 12.41% 11.04% 3.1M

Health Technology

| -3.57% | O: 0.0% H: 0.0% C: -4.29%
IMAB | $1.805 0.28% 0.28% 110K

Health Technology

| -10.45% | O: 2.49% H: 0.97% C: -2.91%
business agreement china

Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts
Published: 2024-02-01 (Crawled : 13:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M

Health Technology

| 0.93% | O: 2.8% H: 0.55% C: 0.18%
fda ceo innovation

Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
Published: 2024-01-25 (Crawled : 12:30) - globenewswire.com
AMRX | $6.07 12.41% 11.04% 3.1M

Health Technology

| -0.55% | O: 1.57% H: 0.73% C: -0.82%
ipx203 license pharmaceuticals therapeutics agreement

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001628280-24-009481	4	2024-03-06	2024-03-04	Buy	A	1333334	1333334
0001628280-24-009481	4	2024-03-06	2024-03-04	Buy	A	370370	370370
0001628280-24-009480	4	2024-03-06	2024-03-04	Buy	A	1333334	1333334
0001628280-24-009480	4	2024-03-06	2024-03-04	Buy	A	370370	370370